Works matching IS 11738804 AND DT 2022 AND VI 36 AND IP 4

Results: 10

Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (VigilVacCOVID Study).
Published in:
BioDrugs, 2022, v. 36, n. 4, p. 509, doi. 10.1007/s40259-022-00543-9
By:
- Sáez-Peñataro, Joaquín;
- Torres, Ferran;
- Bartra, Joan;
- Bascuas, Juan;
- Vilella, Anna;
- Tortajada, Marta;
- Quesada, Sebastiana;
- González, Elisenda;
- López-Suñé, Ester;
- Castells, Antoni;
- Serrano, Sandra;
- Camacho, Concepción;
- Trilla, Antoni;
- Calvo, Gonzalo;
- the VigilVacCOVID Group;
- Sáez-Peñataro, Joaquin;
- Bertran, Maria-Jesús;
- Carrera, Cristina;
- Galisteo, Maria;
- Gómez, Sara
Publication type:
Article
Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
Published in:
BioDrugs, 2022, v. 36, n. 4, p. 521, doi. 10.1007/s40259-022-00542-w
By:
- Jin, Yinzhu;
- Landon, Joan E.;
- Krueger, Whitney;
- Liede, Alexander;
- Desai, Rishi J.;
- Kim, Seoyoung C.
Publication type:
Article
Pharmacists' Perspectives of Biosimilars: A Systematic Review.
Published in:
BioDrugs, 2022, v. 36, n. 4, p. 489, doi. 10.1007/s40259-022-00541-x
By:
- Mohd Sani, Noraisyah;
- Aziz, Zoriah;
- Panickar, Rema;
- Kamarulzaman, Adeeba
Publication type:
Article
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Published in:
BioDrugs, 2022, v. 36, n. 4, p. 537, doi. 10.1007/s40259-022-00540-y
By:
- Luukkanen, Saana V.;
- Tolonen, Hanna M.;
- Airaksinen, Marja;
- Saarukka, Laura S. M.
Publication type:
Article
Progress with RNA Interference for the Treatment of Primary Hyperoxaluria.
Published in:
BioDrugs, 2022, v. 36, n. 4, p. 437, doi. 10.1007/s40259-022-00539-5
By:
- Sawyer, Kathryn;
- Leahy, Stephen;
- Wood, Kyle D.
Publication type:
Article
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One.
Published in:
BioDrugs, 2022, v. 36, n. 4, p. 431, doi. 10.1007/s40259-022-00538-6
By:
- Park, Joseph P.;
- Jung, Byoungin;
- Park, Hyung Ki;
- Shin, Donghoon;
- Jung, Jin Ah;
- Ghil, Jeehoon;
- Han, Jihyun;
- Kim, Kyung Ah;
- Woollett, Gillian R.
Publication type:
Article
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis.
Published in:
BioDrugs, 2022, v. 36, n. 4, p. 459, doi. 10.1007/s40259-022-00537-7
By:
- Abadie, Bryan Q.;
- Cremer, Paul C.
Publication type:
Article
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management.
Published in:
BioDrugs, 2022, v. 36, n. 4, p. 443, doi. 10.1007/s40259-022-00536-8
By:
- Luxi, Nicoletta;
- Giovanazzi, Alexia;
- Arcolaci, Alessandra;
- Bonadonna, Patrizia;
- Crivellaro, Maria Angiola;
- Cutroneo, Paola Maria;
- Ferrajolo, Carmen;
- Furci, Fabiana;
- Guidolin, Lucia;
- Moretti, Ugo;
- Olivieri, Elisa;
- Petrelli, Giuliana;
- Zanoni, Giovanna;
- Senna, Gianenrico;
- Trifirò, Gianluca
Publication type:
Article
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy.
Published in:
2022
By:
- Booth, Mary E.;
- Smyth, Elizabeth C.
Publication type:
Correction Notice
Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy.
Published in:
BioDrugs, 2022, v. 36, n. 4, p. 473, doi. 10.1007/s40259-022-00527-9
By:
- Booth, Mary E.;
- Smyth, Elizabeth C.
Publication type:
Article